Sumitomo Chemical is pleased to announce the successful manufacturing of guide RNA (gRNA) for genome editing and achieving 86.5% purity. This marks the first GMP production of gRNA in its newly constructed Oita Plant (Oita, Japan). This was a direct scale-up from laboratory scale, without a trial batch, leveraging Sumitomo’s Standard Manufacturing Method that can be applied to most gRNAs.

The Oita Plant, which started its operation from August 2023, is a state-of-the-art facility equipped for manufacturing long synthetic RNAs such as gRNAs used for CRISPR-Cas9 system. Building on this manufacturing success, Sumitomo will continue to supply high-quality gRNA for genome editing and contribute to the widespread adoption of genome-editing therapy.

For inquiries, please click here.